Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi/Regeneron Get Reprieve: Praluent Can Stay On Market For Now

Feb 09 2017

• By Brenda Sandburg

court house

Related Content

Praluent Fate Uncertain After Amgen Wins PCSK9 Patent Battle

Mar 17 2016

PCSK9 Patent Fight: Amgen Opposes Doctor Efforts To Keep Praluent On Market

Jan 27 2017

‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales

Jan 06 2017

Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear

Feb 03 2017

Related Companies

Sanofi

Regeneron Pharmaceuticals, Inc.

Amgen, Inc.

Additional Topics

Intellectual Property Legal Issues Policy BioPharmaceutical

More from Legal & IP

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window